JPWO2021191838A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021191838A5 JPWO2021191838A5 JP2022557102A JP2022557102A JPWO2021191838A5 JP WO2021191838 A5 JPWO2021191838 A5 JP WO2021191838A5 JP 2022557102 A JP2022557102 A JP 2022557102A JP 2022557102 A JP2022557102 A JP 2022557102A JP WO2021191838 A5 JPWO2021191838 A5 JP WO2021191838A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- group
- methoxy
- tetrahydro
- methylpyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 208000010877 cognitive disease Diseases 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 6
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 5
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 208000029560 autism spectrum disease Diseases 0.000 claims 4
- 206010027175 memory impairment Diseases 0.000 claims 4
- 239000002207 metabolite Substances 0.000 claims 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- -1 2,2,2-trifluoro-1-[6-({5-methyl-3-[6-(trifluoromethyl)pyridin-3-yl]-1,2-oxazol-4-yl}methoxy)- 1,2,3,4-tetrahydro-2,7-naphthyridin-2-yl]ethane-1-one Chemical compound 0.000 claims 2
- 208000009575 Angelman syndrome Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims 2
- 208000027626 Neurocognitive disease Diseases 0.000 claims 2
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 2
- 208000006289 Rett Syndrome Diseases 0.000 claims 2
- 208000027520 Somatoform disease Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000007278 cognition impairment Effects 0.000 claims 2
- 230000006999 cognitive decline Effects 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000004970 halomethyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 208000027753 pain disease Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- HYQHYVSPOHMFAL-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)N1CC2=CN=C(C=C2CC1)OCC1=C(N=NN1C=1C=NC(=CC=1)C)C Chemical compound C(C1=CC=CC=C1)(=O)N1CC2=CN=C(C=C2CC1)OCC1=C(N=NN1C=1C=NC(=CC=1)C)C HYQHYVSPOHMFAL-UHFFFAOYSA-N 0.000 claims 1
- YNUSMBWLLBZKFW-UHFFFAOYSA-N C1(CC1)C(=O)N1CC2=CN=C(C=C2CC1)OCC1=C(N=NN1C=1C=NC(=CC=1)C)C Chemical compound C1(CC1)C(=O)N1CC2=CN=C(C=C2CC1)OCC1=C(N=NN1C=1C=NC(=CC=1)C)C YNUSMBWLLBZKFW-UHFFFAOYSA-N 0.000 claims 1
- ZFUMTAHHKXOOAE-UHFFFAOYSA-N C1(CC1)C(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C Chemical compound C1(CC1)C(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C ZFUMTAHHKXOOAE-UHFFFAOYSA-N 0.000 claims 1
- LVJBBXYWAWPZCO-UHFFFAOYSA-N C1(CC1)C(=O)N1CC=2N=NC(=CC=2CC1)OCC=1C(=NOC=1C)C=1C=CC(=NC=1)C Chemical compound C1(CC1)C(=O)N1CC=2N=NC(=CC=2CC1)OCC=1C(=NOC=1C)C=1C=CC(=NC=1)C LVJBBXYWAWPZCO-UHFFFAOYSA-N 0.000 claims 1
- ILMWTZMZVRTFFA-UHFFFAOYSA-N C1(CC1)NC(=O)N1CC=2N=NC(=CC=2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C Chemical compound C1(CC1)NC(=O)N1CC=2N=NC(=CC=2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C ILMWTZMZVRTFFA-UHFFFAOYSA-N 0.000 claims 1
- ZIFLIKRPKKAEMG-UHFFFAOYSA-N C1(CCC1)C(=O)N1CC2=CN=C(C=C2CC1)OCC1=C(N=NN1C=1C=NC(=CC=1)C)C Chemical compound C1(CCC1)C(=O)N1CC2=CN=C(C=C2CC1)OCC1=C(N=NN1C=1C=NC(=CC=1)C)C ZIFLIKRPKKAEMG-UHFFFAOYSA-N 0.000 claims 1
- QXEDALDPHGEJDY-UHFFFAOYSA-N C1(CCC1)C(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C Chemical compound C1(CCC1)C(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C QXEDALDPHGEJDY-UHFFFAOYSA-N 0.000 claims 1
- IQMXWPWBRBJEBB-UHFFFAOYSA-N C1=C(N=CC(=C1)C=1C(=C(ON=1)C)COC1=NC=C2C(=C1)CCN(C(=O)C1CCC(=O)N(C1)C)C2)C Chemical compound C1=C(N=CC(=C1)C=1C(=C(ON=1)C)COC1=NC=C2C(=C1)CCN(C(=O)C1CCC(=O)N(C1)C)C2)C IQMXWPWBRBJEBB-UHFFFAOYSA-N 0.000 claims 1
- VNDRBOBTNZAMFW-UHFFFAOYSA-N C1=C(N=CC(C=2C(=C(ON=2)C)COC2=CC=3CCN(C(=O)C4CC(=O)N(C4)C)CC=3C=N2)=C1)C Chemical compound C1=C(N=CC(C=2C(=C(ON=2)C)COC2=CC=3CCN(C(=O)C4CC(=O)N(C4)C)CC=3C=N2)=C1)C VNDRBOBTNZAMFW-UHFFFAOYSA-N 0.000 claims 1
- XWLDUEXQLSKZMA-UHFFFAOYSA-N C1=C(N=CC(C=2C(=C(ON=2)C)COC2=NN=C3C(=C2)CCN(C(=O)C2CCC2)C3)=C1)C Chemical compound C1=C(N=CC(C=2C(=C(ON=2)C)COC2=NN=C3C(=C2)CCN(C(=O)C2CCC2)C3)=C1)C XWLDUEXQLSKZMA-UHFFFAOYSA-N 0.000 claims 1
- QTANMKKDFSOQHK-UHFFFAOYSA-N CC(C(=O)N1CC2=CN=C(C=C2CC1)OCC1=C(N=NN1C=1C=NC(=CC=1)C)C)(C)C Chemical compound CC(C(=O)N1CC2=CN=C(C=C2CC1)OCC1=C(N=NN1C=1C=NC(=CC=1)C)C)(C)C QTANMKKDFSOQHK-UHFFFAOYSA-N 0.000 claims 1
- QDECRHCTXRSXIO-UHFFFAOYSA-N CC(C(=O)N1CC2=CN=C(C=C2CC1)OCC1=C(N=NN1C=1C=NC(=CC=1)C)C)C Chemical compound CC(C(=O)N1CC2=CN=C(C=C2CC1)OCC1=C(N=NN1C=1C=NC(=CC=1)C)C)C QDECRHCTXRSXIO-UHFFFAOYSA-N 0.000 claims 1
- PTMQMICVLMPCSE-UHFFFAOYSA-N CC(C(=O)N1CC=2N=NC(=CC=2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C)C Chemical compound CC(C(=O)N1CC=2N=NC(=CC=2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C)C PTMQMICVLMPCSE-UHFFFAOYSA-N 0.000 claims 1
- JQUBDYHKARFNOX-UHFFFAOYSA-N CC(C)C(N(CCC1=C2)CC1=CN=C2OCC1=C(C)N=NN1C1=CC=C(C(F)(F)F)N=C1)=O Chemical compound CC(C)C(N(CCC1=C2)CC1=CN=C2OCC1=C(C)N=NN1C1=CC=C(C(F)(F)F)N=C1)=O JQUBDYHKARFNOX-UHFFFAOYSA-N 0.000 claims 1
- SIYSWGVPZPZDBD-UHFFFAOYSA-N CC(CC(=O)N1CC2=CN=C(C=C2CC1)OCC1=C(N=NN1C=1C=NC(=CC=1)C)C)C Chemical compound CC(CC(=O)N1CC2=CN=C(C=C2CC1)OCC1=C(N=NN1C=1C=NC(=CC=1)C)C)C SIYSWGVPZPZDBD-UHFFFAOYSA-N 0.000 claims 1
- RINRLTWYKYSBFU-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C(F)(F)F)COC1=CC2=C(N=N1)CN(CC2)C(C)=O Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C(F)(F)F)COC1=CC2=C(N=N1)CN(CC2)C(C)=O RINRLTWYKYSBFU-UHFFFAOYSA-N 0.000 claims 1
- DYNIVFJWIKLNIT-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C(F)(F)F)COC=1C=C2CCN(CC2=CN=1)C(=O)OC(C)(C)C Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C(F)(F)F)COC=1C=C2CCN(CC2=CN=1)C(=O)OC(C)(C)C DYNIVFJWIKLNIT-UHFFFAOYSA-N 0.000 claims 1
- ZMHXXOCCYFRKID-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C(F)(F)F)COC=1C=C2CCN(CC2=CN=1)C(C)=O Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C(F)(F)F)COC=1C=C2CCN(CC2=CN=1)C(C)=O ZMHXXOCCYFRKID-UHFFFAOYSA-N 0.000 claims 1
- VIQDJIRJZPPTNU-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC1=CC2=C(N=N1)CN(CC2)C(=O)N1CCOCC1 Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC1=CC2=C(N=N1)CN(CC2)C(=O)N1CCOCC1 VIQDJIRJZPPTNU-UHFFFAOYSA-N 0.000 claims 1
- HVGVJLSKJUMZSG-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC1=CC2=C(N=N1)CN(CC2)C(=O)NC1CCOCC1 Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC1=CC2=C(N=N1)CN(CC2)C(=O)NC1CCOCC1 HVGVJLSKJUMZSG-UHFFFAOYSA-N 0.000 claims 1
- SYYZNHLJDHFAGS-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC1=CC2=C(N=N1)CN(CC2)C(C)=O Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC1=CC2=C(N=N1)CN(CC2)C(C)=O SYYZNHLJDHFAGS-UHFFFAOYSA-N 0.000 claims 1
- AGOMBYOZLMWWDP-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC1=CC2=C(N=N1)CN(CC2)C(CC)=O Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC1=CC2=C(N=N1)CN(CC2)C(CC)=O AGOMBYOZLMWWDP-UHFFFAOYSA-N 0.000 claims 1
- AWCBSPGJALTULS-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(=O)C1=CC=NC=C1 Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(=O)C1=CC=NC=C1 AWCBSPGJALTULS-UHFFFAOYSA-N 0.000 claims 1
- DIQWGZJCPNVMOK-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(=O)C1CC(N(C1)C(C)C)=O Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(=O)C1CC(N(C1)C(C)C)=O DIQWGZJCPNVMOK-UHFFFAOYSA-N 0.000 claims 1
- RINCAUCNIKPMIA-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(=O)C1CCOCC1 Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(=O)C1CCOCC1 RINCAUCNIKPMIA-UHFFFAOYSA-N 0.000 claims 1
- XIBDTHYOJSVAHD-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(=O)C1COCC1 Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(=O)C1COCC1 XIBDTHYOJSVAHD-UHFFFAOYSA-N 0.000 claims 1
- MUBAUMVTHVFPGJ-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(=O)C1COCCC1 Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(=O)C1COCCC1 MUBAUMVTHVFPGJ-UHFFFAOYSA-N 0.000 claims 1
- GBYSVTGKAWYCKF-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(=O)C=1C=NC=CC=1 Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(=O)C=1C=NC=CC=1 GBYSVTGKAWYCKF-UHFFFAOYSA-N 0.000 claims 1
- ZFPCVFMSSSQYCQ-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(=O)N1CCCC1 Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(=O)N1CCCC1 ZFPCVFMSSSQYCQ-UHFFFAOYSA-N 0.000 claims 1
- XUWCWRVOBUANAV-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(=O)OC(C)(C)C Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(=O)OC(C)(C)C XUWCWRVOBUANAV-UHFFFAOYSA-N 0.000 claims 1
- QNKIFGXUKZAWLR-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(C)=O Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(C)=O QNKIFGXUKZAWLR-UHFFFAOYSA-N 0.000 claims 1
- PCCDEXVBBFWKPX-UHFFFAOYSA-N CC1=C(COC2=NC=C(CN(CC3)C(C4CCOCC4)=O)C3=C2)N(C2=CC=C(C)N=C2)N=N1 Chemical compound CC1=C(COC2=NC=C(CN(CC3)C(C4CCOCC4)=O)C3=C2)N(C2=CC=C(C)N=C2)N=N1 PCCDEXVBBFWKPX-UHFFFAOYSA-N 0.000 claims 1
- LBGXWZSBIXDPHU-UHFFFAOYSA-N CC1=NC=C(C=C1)C1=NOC(=C1COC1=CC2=C(N=N1)CN(CC2)C(=O)C1CCOCC1)C Chemical compound CC1=NC=C(C=C1)C1=NOC(=C1COC1=CC2=C(N=N1)CN(CC2)C(=O)C1CCOCC1)C LBGXWZSBIXDPHU-UHFFFAOYSA-N 0.000 claims 1
- ZFOPPMVJRANOKT-UHFFFAOYSA-N CC1=NOC(=C1)C(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C Chemical compound CC1=NOC(=C1)C(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C ZFOPPMVJRANOKT-UHFFFAOYSA-N 0.000 claims 1
- URZRTPGWQWGLCB-UHFFFAOYSA-N CC=1C=NOC=1C(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C Chemical compound CC=1C=NOC=1C(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C URZRTPGWQWGLCB-UHFFFAOYSA-N 0.000 claims 1
- IDXSDRUMIKGLRY-UHFFFAOYSA-N CC=1N=NN(C=1COC=1C=C2CCN(CC2=CN=1)C(C)=O)C=1C=NC(=CC=1)C Chemical compound CC=1N=NN(C=1COC=1C=C2CCN(CC2=CN=1)C(C)=O)C=1C=NC(=CC=1)C IDXSDRUMIKGLRY-UHFFFAOYSA-N 0.000 claims 1
- VHWPCRYUJQAOKP-UHFFFAOYSA-N CC=1N=NN(C=1COC=1C=C2CCN(CC2=CN=1)C(C)=O)C=1C=NC(=CC=1)C(F)(F)F Chemical compound CC=1N=NN(C=1COC=1C=C2CCN(CC2=CN=1)C(C)=O)C=1C=NC(=CC=1)C(F)(F)F VHWPCRYUJQAOKP-UHFFFAOYSA-N 0.000 claims 1
- DSFSFAXBXNMZMS-UHFFFAOYSA-N CC=1N=NN(C=1COC=1C=C2CCN(CC2=CN=1)C(CC)=O)C=1C=NC(=CC=1)C Chemical compound CC=1N=NN(C=1COC=1C=C2CCN(CC2=CN=1)C(CC)=O)C=1C=NC(=CC=1)C DSFSFAXBXNMZMS-UHFFFAOYSA-N 0.000 claims 1
- ZCXGRPWCBZTREC-UHFFFAOYSA-N CC=1N=NN(C=1COC=1C=C2CCN(CC2=CN=1)C(CC)=O)C=1C=NC(=CC=1)C(F)(F)F Chemical compound CC=1N=NN(C=1COC=1C=C2CCN(CC2=CN=1)C(CC)=O)C=1C=NC(=CC=1)C(F)(F)F ZCXGRPWCBZTREC-UHFFFAOYSA-N 0.000 claims 1
- LQNAQKUPWGKVDS-UHFFFAOYSA-N CCN(CC(C1)C(N(CCC2=C3)CC2=CN=C3OCC2=C(C)ON=C2C2=CC=C(C)N=C2)=O)C1=O Chemical compound CCN(CC(C1)C(N(CCC2=C3)CC2=CN=C3OCC2=C(C)ON=C2C2=CC=C(C)N=C2)=O)C1=O LQNAQKUPWGKVDS-UHFFFAOYSA-N 0.000 claims 1
- PKJJLVVRVLEWCM-UHFFFAOYSA-N CN(C(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C)C Chemical compound CN(C(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C)C PKJJLVVRVLEWCM-UHFFFAOYSA-N 0.000 claims 1
- AAPLJCOBFIPAMM-OAQYLSRUSA-N CN1C(CC[C@@H]1C(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C)=O Chemical compound CN1C(CC[C@@H]1C(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C)=O AAPLJCOBFIPAMM-OAQYLSRUSA-N 0.000 claims 1
- AAPLJCOBFIPAMM-NRFANRHFSA-N CN1C(CC[C@H]1C(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C)=O Chemical compound CN1C(CC[C@H]1C(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C)=O AAPLJCOBFIPAMM-NRFANRHFSA-N 0.000 claims 1
- CTPNOSSWQSPKSS-UHFFFAOYSA-N CS(=O)(=O)CC(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C Chemical compound CS(=O)(=O)CC(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C CTPNOSSWQSPKSS-UHFFFAOYSA-N 0.000 claims 1
- ZHONJEGUSLFQQY-UHFFFAOYSA-N CS(=O)(=O)CC(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C(F)(F)F Chemical compound CS(=O)(=O)CC(=O)N1CC2=CN=C(C=C2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C(F)(F)F ZHONJEGUSLFQQY-UHFFFAOYSA-N 0.000 claims 1
- HIHKLJHUBCVIMI-UHFFFAOYSA-N FCC(=O)N1CC2=CN=C(C=C2CC1)OCC1=C(N=NN1C=1C=NC(=CC=1)C)C Chemical compound FCC(=O)N1CC2=CN=C(C=C2CC1)OCC1=C(N=NN1C=1C=NC(=CC=1)C)C HIHKLJHUBCVIMI-UHFFFAOYSA-N 0.000 claims 1
- INNGKAJNPAYZLC-UHFFFAOYSA-N FCC(=O)N1CC=2N=NC(=CC=2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C Chemical compound FCC(=O)N1CC=2N=NC(=CC=2CC1)OCC=1C(=NOC=1C)C=1C=NC(=CC=1)C INNGKAJNPAYZLC-UHFFFAOYSA-N 0.000 claims 1
- PCDHSSHKDZYLLI-UHFFFAOYSA-N butan-1-one Chemical compound CCC[C]=O PCDHSSHKDZYLLI-UHFFFAOYSA-N 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical group CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP2000113 | 2020-03-26 | ||
HUP2000113 | 2020-03-26 | ||
PCT/IB2021/052486 WO2021191838A1 (en) | 2020-03-26 | 2021-03-25 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023520647A JP2023520647A (ja) | 2023-05-18 |
JPWO2021191838A5 true JPWO2021191838A5 (zh) | 2024-03-11 |
Family
ID=89666363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022557102A Pending JP2023520647A (ja) | 2020-03-26 | 2021-03-25 | GABA Aアルファ5受容体調節剤としてのナフチリジンおよびピリド[3,4-c]ピリダジン誘導体 |
Country Status (20)
Country | Link |
---|---|
US (1) | US20240067637A1 (zh) |
EP (1) | EP4126859A1 (zh) |
JP (1) | JP2023520647A (zh) |
KR (1) | KR20220160061A (zh) |
CN (1) | CN115348962A (zh) |
AR (1) | AR121666A1 (zh) |
AU (1) | AU2021244926A1 (zh) |
BR (1) | BR112022019128A2 (zh) |
CA (1) | CA3171441A1 (zh) |
CL (1) | CL2022002568A1 (zh) |
CO (1) | CO2022014877A2 (zh) |
CU (1) | CU20220058A7 (zh) |
EC (1) | ECSP22082367A (zh) |
IL (1) | IL296716A (zh) |
JO (1) | JOP20220219A1 (zh) |
MX (1) | MX2022011933A (zh) |
PE (1) | PE20221836A1 (zh) |
TW (1) | TW202202495A (zh) |
WO (1) | WO2021191838A1 (zh) |
ZA (1) | ZA202211414B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP2100338A1 (hu) * | 2021-09-29 | 2023-04-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2728900B1 (fr) * | 1994-12-29 | 1997-01-31 | Synthelabo | Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique |
SE0403085D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
KR101022082B1 (ko) * | 2005-10-11 | 2011-03-17 | 에프. 호프만-라 로슈 아게 | 아이소옥사졸 유도체 |
CA2628667A1 (en) * | 2005-11-09 | 2007-05-18 | F. Hoffmann-La Roche Ag | 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives |
HU230518B1 (hu) | 2005-12-20 | 2016-10-28 | Richter Gedeon Nyrt. | Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények |
HUP0600810A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
HUP0600808A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them |
HUP0600809A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
US8742097B2 (en) * | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
CA2828578A1 (en) * | 2011-03-04 | 2012-09-13 | Lexicon Pharmaceuticals, Inc. | Mst1 kinase inhibitors and methods of their use |
DK2937349T3 (en) | 2011-03-23 | 2017-02-20 | Amgen Inc | CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 |
US9206160B2 (en) * | 2012-06-26 | 2015-12-08 | Saniona Aps | Phenyl triazole derivative and its use for modulating the GABAA receptor complex |
CA2876780A1 (en) | 2012-06-26 | 2014-01-03 | Saniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
WO2014001279A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
WO2014001278A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
CN102924452B (zh) * | 2012-11-16 | 2015-01-21 | 苏州施亚生物科技有限公司 | 5,6,7,8-四氢-2H-吡啶并[3,4-c]哒嗪-3-酮的合成方法 |
HUP1300139A2 (en) | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
JP6883988B2 (ja) | 2013-12-20 | 2021-06-09 | エージンバイオ, インコーポレイテッド | ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 |
US9296747B1 (en) * | 2014-10-10 | 2016-03-29 | Allergan, Inc. | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 |
KR20180030545A (ko) * | 2015-06-22 | 2018-03-23 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 바이사이클릭 헤테로사이클릭 아미드 유도체 |
MX2018002446A (es) | 2015-08-28 | 2019-01-10 | Abbvie Inc | Compuestos heterociclicos fusionados como moduladores s1p. |
EP4129297A1 (en) | 2016-03-18 | 2023-02-08 | UWM Research Foundation, Inc. | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists |
CR20190268A (es) * | 2016-12-08 | 2019-07-11 | Hoffmann La Roche | Nuevos deribados de isoxazolil éter como pam de gaba a alfa5 |
US20200268728A1 (en) * | 2016-12-20 | 2020-08-27 | Sumitomo Dainippon Pharma Co., Ltd. | Drug targeting cancer stem cell |
HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
HU231057B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt | Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok |
CA3120971A1 (en) | 2017-11-27 | 2019-05-31 | Dart Neuroscience, Llc | Substituted furanopyrimidine compounds as pde1 inhibitors |
TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素V1a受體拮抗劑之三環化合物 |
HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
SG11202012200QA (en) | 2018-06-13 | 2021-01-28 | Hoffmann La Roche | New isoxazolyl ether derivatives as gaba a alpha5 pam |
HU231414B1 (hu) | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
HU231333B1 (hu) | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
HU231478B1 (hu) | 2018-07-13 | 2024-02-28 | Richter Gedeon Nyrt. | Szubsztituált (aza)indol származékok |
BR102019014802A2 (pt) * | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
HU231223B1 (hu) * | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
-
2021
- 2021-03-11 TW TW110108696A patent/TW202202495A/zh unknown
- 2021-03-25 CU CU2022000058A patent/CU20220058A7/es unknown
- 2021-03-25 IL IL296716A patent/IL296716A/en unknown
- 2021-03-25 CN CN202180023958.0A patent/CN115348962A/zh active Pending
- 2021-03-25 US US17/907,174 patent/US20240067637A1/en active Pending
- 2021-03-25 WO PCT/IB2021/052486 patent/WO2021191838A1/en active Application Filing
- 2021-03-25 KR KR1020227037372A patent/KR20220160061A/ko unknown
- 2021-03-25 BR BR112022019128A patent/BR112022019128A2/pt unknown
- 2021-03-25 PE PE2022002114A patent/PE20221836A1/es unknown
- 2021-03-25 JP JP2022557102A patent/JP2023520647A/ja active Pending
- 2021-03-25 CA CA3171441A patent/CA3171441A1/en active Pending
- 2021-03-25 EP EP21715334.5A patent/EP4126859A1/en active Pending
- 2021-03-25 MX MX2022011933A patent/MX2022011933A/es unknown
- 2021-03-25 JO JOP/2022/0219A patent/JOP20220219A1/ar unknown
- 2021-03-25 AU AU2021244926A patent/AU2021244926A1/en active Pending
- 2021-03-26 AR ARP210100754A patent/AR121666A1/es unknown
-
2022
- 2022-09-22 CL CL2022002568A patent/CL2022002568A1/es unknown
- 2022-10-18 ZA ZA2022/11414A patent/ZA202211414B/en unknown
- 2022-10-19 CO CONC2022/0014877A patent/CO2022014877A2/es unknown
- 2022-10-22 EC ECSENADI202282367A patent/ECSP22082367A/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107089985B (zh) | 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3-d]嘧啶衍生物 | |
JP4302762B2 (ja) | 複素環式芳香族キノリン化合物およびpde10阻害剤としてのその使用 | |
RU2470931C2 (ru) | Производные оксадиазола и их применение в качестве потенцирующих средств метаботропных глутаматных рецепторов-842 | |
AU2012314518B2 (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
JP2020530446A5 (zh) | ||
JP2018526399A (ja) | ヒトキチナーゼ阻害剤として有用な置換アミノトリアゾール | |
KR20140084146A (ko) | 신규 옥사진 유도체 및 질환의 치료에서의 그의 용도 | |
AU2006239418A1 (en) | Novel oxadiazole derivatives and their medical use | |
JP2013523884A5 (zh) | ||
KR20150107871A (ko) | 티아디아졸 유사체 및 smn-결핍-관련-상태의 치료 방법 | |
JP2008540637A5 (zh) | ||
JP2013539777A5 (zh) | ||
HRP20100401T1 (hr) | DERIVATI PIRAZOLO/3,4-d/AZEPINA KAO HISTAMINSKI H3 ANTAGONISTI | |
RU2019123319A (ru) | Пиразолопиримидины и способы их применения | |
WO2019134978A1 (en) | 1, 3, 4, 5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer's disease | |
JP2013533868A (ja) | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 | |
JP2020526549A5 (zh) | ||
TW201321353A (zh) | 胺基甲酸酯/尿素衍生物 | |
JP2009500366A5 (zh) | ||
SG177691A1 (en) | Sphingosine-1-phosphate receptor agonists | |
WO2016201168A1 (en) | Oxadiazine compounds and methods of use thereof | |
JP2022501429A (ja) | 特定の白血病を治療するための化合物 | |
WO2023224894A1 (en) | Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
US20240174683A1 (en) | Map4k1 inhibitors | |
JP2017226661A (ja) | 脆弱x症候群、パーキンソン病又は逆流性疾患の治療に有用なジアゼピノン誘導体 |